BDP5290
BDP5290 is a potent inhibitor of both ROCK and MRCK with IC50s of 5 nM, 50 nM, 10 nM and 100 nM for ROCK1, ROCK2, MRCKα and MRCKβ, respectively.
Product Specifications
CAS Number
1817698-21-7
UNSPSC
12352005
Hazard Statement
H302-H315-H319
Target
ROCK
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Cytoskeleton; Stem Cell/Wnt; TGF-beta/Smad
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/BDP5290.html
Purity
98.90
Solubility
DMSO : 12.5 mg/mL (ultrasonic)
Smiles
ClC(C(C(NC1=CNN=C1C2=NC=CC=C2)=O)=N3)=CN3C4CCNCC4
Molecular Formula
C17H18ClN7O
Molecular Weight
371.82
Precautions
P264-P270-P280-P302+P352-P305+P351+P338-P330-P362+P364-P501
References & Citations
[1]Gandalovi?ová A, et al. Migrastatics-Anti-metastatic and Anti-invasion Drugs: Promises and Challenges. Trends Cancer. 2017 Jun;3 (6) :391-406.|[2]Unbekandt M, et al. A novel small-molecule MRCK inhibitor blocks cancer cell invasion. Cell Commun Signal. 2014 Oct 5;12:54.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
ROCK1; ROCK2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
CXB34849-01 50 mg
3-Methyl-1- (6-methylpyridazin-3-yl) -1H-pyrazol-5-amine
Sign In for Pricing
View Details CXB34849-02 0.5 g
3-Methyl-1- (6-methylpyridazin-3-yl) -1H-pyrazol-5-amine
Sign In for Pricing
View Details